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Abstract A recent study in rheumatoid arthritis (RA) patients
using electrical vagus nerve stimulation (VNS) to activate the
inflammatory reflex has shown promising effects on disease
activity. Innervation by the autonomic nerve system might be
involved in the regulation of many endocrine and metabolic
processes and could therefore theoretically lead to unwanted
side effects. Possible effects of VNS on secretion of hormones
are currently unknown. Therefore, we evaluated the effects of
a single VNS on plasma levels of pituitary hormones and
parameters of postprandial metabolism. Six female patients
with RAwere studied twice in balanced assignment (crossover
design) to either VNS or no stimulation. The patients selected
for this substudy had been on VNS therapy daily for at least
3 months and at maximum of 24 months. We compared 10-,
20-, and 30-min poststimulus levels to baseline levels, and a 4-
h mixed meal test was performed 30 min after VNS. We also
determined energy expenditure (EE) by indirect calorimetry
before and after VNS. VNS did not affect pituitary hormones
(growth hormone, thyroid stimulating hormone, adrenocorti-
cotropic hormone, prolactin, follicle-stimulating hormone,
and luteinizing hormone), postprandial metabolism, or EE.
Of note, VNS reduced early postprandial insulin secretion,
but not AUC of postprandial plasma insulin levels. Cortisol
and catecholamine levels in serum did not change significant-
ly. Short stimulation of vagal activity by VNS reduces early
postprandial insulin secretion, but not other hormone levels
and postprandial response. This suggests VNS as a safe treat-
ment for RA patients.
Keywords Brain . Clinical trials andmethods . Endocrine .
Gastrointestinal . Hormones .Metabolic disease .
Metabolomics . Rheumatoid arthritis . Study design
Introduction
The autonomous nervous system and the immune system in-
teract in both directions via neurotransmitters, cytokines, and
hormones [1, 2]. The parasympathetic nervous system, which
consists mainly of the vagus nerve, includes afferent nerves
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that signal the state of the viscera to the central nervous system
[3, 4]. The so-called inflammatory reflex represents a reflex
circuit defined by signals that travel in the vagus nerve to
inhibit monocyte and macrophage production of tumor necro-
sis factor (TNF) and other cytokines [5]. Of interest, recent
prospective observational studies indicate that impaired con-
stitutive vagus nerve activity precedes the development of
clinically manifest rheumatoid arthritis (RA) [6]. Activation
of this pathway through electrical vagus nerve stimulation
(VNS) could be a feasible and effective treatment in reducing
pathological systemic inflammation in RA and other inflam-
matory diseases like Crohn’s disease [7, 8]. Recently, it has
been shown that free fatty acids, norepinephrine, and pancre-
atic polypeptide levels are increased in individuals at risk for
development of RA and RA patients, compared to healthy
individuals [9]. These findings could suggest the hypothesis
that VNS could influence those peptides and therefore also
(the development of) RA. There is extensive experience with
VNS as a long-term treatment in patients with refractory epi-
lepsy and depression [10, 11]. Recently, a phase 2, open-label
multicentre study showed that VNS in RA patients signifi-
cantly inhibited TNF production and improved disease activ-
ity [12]. In this study, the left vagus nerve was isolated within
the sheath between the carotid artery and the internal jugular
vein and a VNS lead with three helical coiled cuffs was placed
around the vagus nerve. With this approach, we cannot ex-
clude the possibility that VNS has effects in other vagal tar-
gets, such as the pituitary gland and the central nervous
system.
Pituitary hormone levels are known to be partially under
vagal control, as demonstrated by a significant increase in
prolactin (PRL) levels after bilateral vagotomy in rats [13].
In lactating rats, vagotomy blunts the suckling-induced in-
crease of PRL [14]. There are conflicting data on the effect
of VNS on the hypothalamic-pituitary-adrenal (HPA) axis in
animal models [15, 16]. However, there are currently no data
on the effects of VNS on PRL levels in humans. One study has
suggested a reduction in the adrenocorticotropic hormone
(ACTH) response upon corticotropin-releasing hormone
(CRH) challenge after short-term VNS (during 2 weeks) in
patients with chronic depression [17].
The vagus nerve also regulates metabolic activity through
visceral afferent and efferent fibers. Afferent signals from
hormones, chemokines, and nutrients inform the brain on
feeding and energy status. This could indirectly influence
thermoregulation by modulation of CRH release from the
hypothalamus [18]. Selective efferent VNS increased serum
insulin levels, although afferent VNS caused a sustained in-
crease in glucose in rats [19]. Parasympathetic hepatic dener-
vation in obese Zucker rats leads to increased cholesterol
levels. In the only available human data, VNS significantly
increased energy expenditure (EE) in patients with refractory
epilepsy [20, 21].
The objective of this pilot study was to assess the acute
response in plasma hormone and nutrient concentrations after
a single VNS, as well as the postprandial metabolic response
in RA patients on daily VNS treatment.
Subjects and methods
Patients
Six female patients with RAwere enrolled. Prior to enrollment
in this substudy, patients first participated in a core study
(NCT01552941) in which they were implanted with a VNS
device to assess safety and efficacy of daily VNS on RA
outcomes [22]. These patients also participate in a long-term
extension of the core study (NCT01552538). Patient partici-
pation in the current substudy was optional.
Subjects were included between October 2013 and
March 2014 in this substudy. The study patients were included
at the Department of Clinical Immunology andRheumatology of
the Academic Medical Center, Amsterdam, the Netherlands.
Enrolled RA patients fulfilled the 2010 ACR/EULAR classifica-
tion criteria for RA [23, 24]. Five patients were using nonsteroi-
dal anti-inflammatory drugs (NSAIDs). All RA patients were
treated with disease-modifying anti-rheumatic drugs
(DMARDs), four patients used corticosteroids till the maximum
dose of ≤7.5 mg/day, and one patient used biologicals. The core
study, the extension, and the current substudy were separately
approved by the institutional review board of the AMC and
performed according to the principles of the Declaration of
Helsinki. All study subjects gave written informed consent for
all study protocols separately.
Study design
Patients were studied twice with balanced assignment (cross-
over design) between VNS and no stimulation during the
course of their regular daily VNS treatment. The study days
were separated by ≤2 weeks to minimize influence of chang-
es in disease activity. Patients were instructed not to activate
the VNS 1 day prior to the study visits. Additionally, they
were instructed not to use alcohol (2 days prior to study visit)
and tobacco products or to drink coffee/tea or ingest any
other caffeine-containing products within 1 day prior to study
visit.
On study days, patients were admitted to the metabolic unit
at 08:00 h after an overnight fast. A catheter was inserted into
a hand/arm vein and kept in a thermoregulated (60 °C) clear
plastic box for sampling of arterialized venous blood. Saline
was used to keep the catheter patent. From t = 0 (09:00 h),
three blood samples were drawn at 10-min intervals for deter-
mination of baseline hormone levels. At t = 30 min (09:30 h),
patients usedmagnet actuation to activate the VNS once or not
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(depending on study day) after which three blood samples
were drawn at 10-min intervals. At t = ‘0 min (10:30 h), a
liquid mixed meal (Nutridrink Compact, Nutricia,
Zoetermeer, the Netherlands) containing 25% of daily EE (es-
timated using the Harrison Benedict equation) was given, after
which blood was drawn at 30-min intervals at ’30, ’60, ’90,
’120, ’150, ’180, ’210 and ’240 min.
VNS and device parameters
The device parameters define modulations of vagus
nerve firing and elicit the neurostimulated inflammatory
reflex. The device parameters for each patient, including
pulse frequency, pulse duration and output current, and
VNS stimulation are detailed in Table 1. The output
current was set at the maximum level tolerated for each
patient with a maximum limit of 2.0 mA. For all pa-
tients, the signal frequency was 10 Hz with a pulse
duration of 250 μs. The frequency of daily stimulations
was between one time and eight times daily. The pa-
tients selected for this substudy had used VNS for at
least 3 months and at maximum of 24 months.
Confirmation of VNS activity after magnet actuation
was obtained by noting physical signs of vagal nerve
activity, such as transient hoarseness, coughing, and
palpitations.
EE and HRV
Oxygen consumption and carbon dioxide production were
measured for 20 min in a supine position using a venti-
lated hood system (Vmax Encore 29; SensorMedics,
Anaheim, CA). EE was calculated from oxygen consump-
tion and carbon dioxide production as reported previously
[25]. EE and eardrum temperature were measured at base-
line (t = −30 min; 08:30 h), poststimulation (t = 60 min;
10:00 h), and postprandial (t = ’120 min; 12:30 h). Heart
rate was measured with an Equivital EQ02 LifeMonitor
(Cambridge, UK). Heart rate variability (low/high frequen-
cy) was calculated using Kubios HRV v2.1 [26].
Clinical parameters
At both study days, the following clinical and disease activity
parameters were obtained: visual analogue scale for global
disease activity (VAS GDA, 0–100 mm), tender joint count
of 28 joints (TJC28), swollen joint count of 28 joints (SJC28),
erythrocyte sedimentation rate (ESR) in millimeters per hour,
C-reactive protein (CRP) levels in milligrams per liter, and
disease activity score of 28 joints (DAS28) [27]. IgM for
rheumatoid factor (IgM-RF) was measured using IgM-RF
Elisa from Hycor Biomedical, Indianapolis, IN (upper limit
of normal (ULN) 49 IU/mL). Anti-citrullinated protein anti-
bodies (ACPA) were measured using anti-CCP2 ELISA
CCPlus (Eurodiagnostica, Nijmegen, the Netherlands (ULN
25 kAU/L)).
Assays
Growth hormone (GH) was measured by chemiluminescence
immuno-assay (Liaison, Diasorin S.p.A., Italy) with an intra-
assay variation of 4.7% at 1.6 mU/L, 3.5% at 6.2 mU/L, and
3.3% at 15.0 mU/L; an inter-assay variation of 10.0% at
0.74 mU/L, 6.0% at 5.1 mU/L, and 6.0% at 18.3 mU/L; and
detection limit of 0.3 mU/L.
Thyroid stimulating hormone (TSH) was measured by
electro-chemiluminescence immuno-assays (ECLIA) on a
Cobas E602 (Roche diagnostics). The intra-assay variation
was 0.9% at 0.156 IU/L and 0.8% at 2.952 IU/L, the inter-
assay variation was 1.4% at 0.156 IU/L and 1.4% at 2.952 IU/
L. The detection limit was 0.01 IU/L.
ACTH was measured by luminescence enzyme immuno-
assay on an Immulite 2000 (Siemens Healthcare Diagnostics
B.V., Breda, the Netherlands). The intra-assay variation was
3.0–8.9%, and the inter-assay variation was 5.2–8.9%. The
detection limit was 1 ng/L.
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Follicle-stimulating hormone (FSH) was measured by
ECLIA on a Cobas E602 (Roche diagnostics, Almere,
the Netherlands), with an intra-assay variation of 1.2% at
9.7 E/L and 1.0% at 56.8 E/L, an inter-assay variation of
2.5% at 9.7 E/L and 2.5% at 56.8 E/L, and detection limit
of 1 IU/L.
Luteinizing hormone (LH) was measured by ECLIA on a
Cobas E602 (Roche diagnostics), with an intra-assay variation
of 1.7% at 4.7 E/L and 1.6% at 52.2 E/L, an inter-assay var-
iation of 1.6% at 4.7 IU/L and 1.6% at 52.2 E/L, and detection
limit of 1 IU/L.
PRL was measured by solid-phase, two-site, time-resolved
fluoro-immunometric assay (Delfia Prolactin, PerkinElmer,
Turku, Finland) with an intra-assay variation of 4% at
5 μg/L and 6% at 24 μg/L, inter-assay variation of 5.5% at
4 μg/L and 7.2% at 50 μg/L, and a detection limit of 1.0 μg/L.
Cortisol was measured by luminescence enzyme immuno-
assay (Siemens Healthcare Diagnostics B.V., Breda, the
Netherlands). The intra-assay variation was 3.6–6.4% and
the inter-assay variation was 4.7–9.0%. The detection limit
was 30 nmol/L.
(Nor)epinephrine was measured with in-house high-perfor-
mance liquid chromatography (HPLC). Norepinephrine and
epinephrine were selectively isolated by liquid-liquid extrac-
tion and derivatized to fluorescent components with 1,2-
diphenylethylenediamine. The fluorescent derivatives were
separated by reversed phase liquid chromatography and de-
tected by scanning fluorescence detection. The intra-assay
variation was 6–8% for norepinephrine and 6–8% for epi-
nephrine. The inter-assay variation was 7–12% for norepi-
nephrine and 7–10% for epinephrine. The detection limit for
both was 0.05 nmol/L.
Four different species of unconjugated bile acids (cholic
acid, chenodeoxycholic acid, deoxycholic acid and
ursodeoxycholic acid) and their glycine- and taurine-
conjugated forms were measured using a highly sensitive
HPLC tandem-MS method as previously reported [28]. Total
bile acid concentrations reported are the calculated sum of all
measured bile acid concentrations.
Free fatty acids (FFAs) were measured by enzymatic meth-
od (NEFAC; Wako Chemicals, Neuss, Germany). The intra-
assay variation was 1% at 0.22 mmol/L and 1% at 0.93 mmol/
L, and the inter-assay variation was 15% at 0.01 mmol/L and
4% at 0.48 mmol/L. The detection limit was 0.02 mmol/L.
Insulin-like growth factor-1 (IGF-1) was measured by
chemiluminescence immuno-assay (Liaison, Diasorin
S.p.A., Italy). The intra-assay variation is 8.0% at
10.3 nmol/L, 8.0% at 17.5 nmol/L, and 9.0% at 23.8 nmol/
L. The inter-assay variation is 10% at 6.9 nmol/L, 7.4% at
30.8 nmol/L, and 8.0% at 59.4 nmol/L. The detection limit
was 0.4 nmol/L.
Insulin was measured by chemiluminescent immunometric
assay (Siemens Healthcare Diagnostics B.V., Breda, the
Netherlands). The intra-assay variation was 6% at 47 pmol/L
and 3% at 609 pmol/L. The inter-assay variation was 4% at
91 pmol/L and 6% at 120 pmol/L. The detection limit was
15 pmol/L.
C-peptide was measured with a RIA (RIA-coat C-peptide,
Byk Sangtec Diagnostica, Dietzenbach, Germany). The inter-
assay variation was 9% at 100 pmol/L and 7% at 500 pmol/L.
The detection limit was 50 pmol/L.
Glucose was measured by spectrophotometric method
(Cobas C702, Roche diagnostics, Almere, the Netherlands).
The intra-assay variation was 0.8% at 5.3 mmol/L and 0.7% at
13.4 mmol/L, and the inter-assay variation was 1.3% at
5.3 mmol/L and 1.1% at 13.4 mmol/L. The detection limit
was 0.1 mmol/L.
Table 2 Patient characteristics
Female RA patients (n = 6)
Day 1: no VNS Day 2: VNS
Age (years) 44 (38–52)
BMI (kg/m2) 22.5 (21.7–22.9)
RR systolic 115 (109–117) 118 (113–127)
RR diastolic 71 (66–75) 75 (71–80)
Heart rate 76 (70–78) 74 (73–83)
Alcohol use: n (%) 3 (50)
Current smoker: n (%) 0 (0)
Previous smoker: n (%) 1 (17)
RF positive: n (%) 4 (67)
ACPA positive: n (%) 2 (33)
Disease duration (months) 130 (74–165)
VAS GDA (mm) 33 (26–40) 35 (25–56)
TJC28 (n) 7 (2–12) 9 (2–12)
SJC28 (n) 3 (1–3) 3 (2–4)
ESR (mm/h) 13 (10–24) 8 (4–11)
CRP (mg/L) 10.1 (4.3–16.7) 4.3 (1.7–15.2)
DAS28 3.97 (3.23–4.96) 3.84 (3.28–4.83)
NSAIDs: n (%) 5 (83)
Corticosteroids: n (%) 4 (67)
Methotrexate: n (%) 6 (100)
Adalimumab: n (%) 1 (17)
Data presented as median (interquartile range) or number (percentage)
VNS vagus nerve stimulation, BMI body mass index, RF rheumatoid
factor, ACPA anti-citrullinated protein antibodies, VAS GDA visual ana-
logue scale (range 0–100 mm) global disease activity, TJC28 tender joint
count of 28 joints, SJC28 swollen joint count of 28 joints, ESR erythro-
cy te sed imenta t ion ra te , CRP C-reac t ive pro te in , HCQ
hydroxychloroquine, NA not applicable
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All hormone measurements, except ACTH, were per-
formed in duplicate. Of these duplicates, means were used
for the analysis.
Statistical analysis
All subjects served as their own controls. All data were analyzed
with nonparametric tests. Data are presented as median and in-
terquartile range (IQR) or mean and standard error of the mean
(SEM). AUC is calculated using the trapezoidal rule. Differences
between study groups were analyzed using Wilcoxon matched
pairs test where appropriate. Categorical data were analyzed
using chi-square test or, if more appropriate, Fisher’s exact test.
Correlations between variables were analyzed using Spearman’s
rank correlation coefficient. Statistical analysis was performed
using IBM SPSS Statistics 18 (SPSS Inc., Chicago, IL).
Results
Study population
Baseline patient characteristics are detailed in Table 2. RA
disease activity, blood pressure, and heart frequency were
not different between both study visits.
Hypothalamic-pituitary axis
The HPA axis was evaluated by analyzing plasma levels
of pituitary hormones (GH, TSH, ACTH, PRL, FSH, and
LH) before and after single VNS. Baseline concentrations
were comparable on study days. VNS did not affect plas-
ma concentrations of any of the pituitary hormone mea-
sured (Fig. 1).
Fig. 1 Pituitary hormones.
Plasma concentrations of GH (a),
TSH (b), ACTH (c), PRL (d),
FSH (e), and LH (f) before and
after VNS. Values are
mean ± SEM. *p < 0.05
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SAS response and inflammation
Basal cortisol and catecholamine levels did not differ between
study days. Neither cortisol nor catecholamines were affected
by VNS (Fig. 2).
Pre- and postprandial metabolism, EE, and HRV
Baseline glucose, insulin, FFA, IGF-1, and bile acid levels
were comparable on study days and were not changed by
VNS alone (Fig. 3). The postprandial glucose response was
slightly decreased by VNS, but this did not reach statistical
significance. VNS did not alter the AUC of postprandial plas-
ma insulin levels. However, the typical early phase insulin
peak was lacking after VNS. VNS tended to reduce plasma
insulin levels at ’30 (P = 0.06). Likewise, first phase insulin
secretion (plasma insulin levels AUC first 60 min after the
meal) tended to be lower after VNS (P = 0.07) (see Fig. 4).
The effect of VNS on insulin could be confirmed by measur-
ing the C-peptide levels. VNS reduced the first phase C-
peptide secretion (plasma C-peptide levels AUC first 60 min
after the meal; P = 0.03). VNS did not affect postprandial bile
acid levels.
Baseline EE was 20.8 ± 0.8 and 20.1 ± 0.5 kcal/kg on the
study day with or without VNS, respectively. Poststimulus EE
was 19.5 ± 1.1 and 19.5 ± 1.3 kcal/kg, respectively. The meal
increased postprandial EE, but this did not differ between
study days. We did not detect any effects of VNS on eardrum
temperature or HRV (data not shown).
Discussion
The results show the effect of VNS on plasma levels of hor-
mones and other parameters of metabolic activity in a cohort
of patients with RA treated with VNS. Overall, a single VNS
reduced the first phase C-peptide secretion but did not affect
these parameters. This suggests that acute VNS treatment in
RA patients has no major interactions with other vagal targets
and supports the concept that VNS is a treatment without
major effects on endocrinologic and metabolic parameters.
VNS did not alter plasma levels of cortisol and catechol-
amine levels in this study. This is in line with animal studies,
in which acute VNS had no effect on either the HPA axis or
the sympathetic-adrenal system (SAS) response [15].
However, there is some evidence that chronic VNS might
facilitate the recovery of the stress-induced HPA axis response
via effective stress coping strategies, e.g., more efficient neg-
ative feedback following a stressor. A study in rats document-
ed that continuous VNS during 3 h increases norepinephrine
Fig. 2 SAS response. Plasma concentrations of epinephrine (a), norepinephrine (b), and cortisol (c) before and after VNS. Values are mean ± SEM.
*p < 0.05
Fig. 3 Postprandial metabolism. Plasma concentrations of glucose (a),
insulin (b), C-peptide (c), free fatty acids (FFA) (d), IGF-1 (e), total bile
acids (BA) (f), and BMR (g).VandM denote VNS andmeal, respectively.
Values are mean ± SEM. *p < 0.05
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concentrations in the brain [16]. Others have examined a
group of patients with chronic depression and observed a re-
duction in the ACTH response upon CRH challenge after
2 weeks of VNS treatment [17]. Thus, although long-term
VNS may have effects on the HPA axis and/or SAS response,
this is not the case for single VNS as shown in this study.
We also observed that VNS did not affect plasma levels of
other pituitary hormones. The evidence on interaction be-
tween vagal activity and pituitary hormone levels in plasma
so far is conflicting. In one report, bilateral vagotomy in rats
resulted in a significant increase in plasma PRL levels after
7 days [14]. In another study, the suckling-induced increase of
prolactin in vagotomized lactating rats was significantly de-
creased [18]. Interestingly, it has been suggested in the litera-
ture that PRL interacts with the immune system, providing a
possible additional pathway for VNS effects on inflammation
[29–31]. However, we did not observe any effects of VNS on
PRL levels. In another study in rats, disruption of the vagus
nerve caused lower GH levels [32].
VNS did not affect postprandial curves of glucose, insulin,
C-peptide, IGF-1, fatty acid, and bile acid levels either before
or after the meal, although the curves of glucose, insulin, C-
peptide, and bile acids suggested a possible VNS effect
(Fig. 4). Recently, it has been suggested that efferent VNS
might be potentially effective in treating type II diabetes
[19]. In contrast to our findings, in Zucker diabetic rats [27],
transauricular VNS decreased fasting glycemia and body
weight increase when applied over a longer time frame. In
the only trial performed in humans, transauricular VNS treat-
ment increased glucose tolerance in impaired glucose tolerant
patients over 12 weeks, though the effect was very small com-
pared to sham treatment. Conversely, in controls, but not in
vagotomized participants, intravenous glucose administration
significantly inhibits pancreatic polypeptide secretion sug-
gesting a vagal glucose sensing mechanism dependent on in-
tact vagal innervation [33].
The link between VNS and plasma insulin levels is less clear,
although vagal activity has been implicated in insulin secretion.
During the first hour after themeal, VNS clearly showed reduced
insulin secretion as evidenced from lower plasma C-peptide
levels. Hyperinsulinemia is present in animal models of obesity
and type 2 diabetes that is thought to be associated with para-
sympathetic drive to the pancreatic ß-cells [34–38].Most of these
experimental studies used indirect approaches to modulate vagal
activity. Direct vagal stimulation effects on insulin secretion have
not been investigated. However, the early pre-absorptive insulin
response to meal ingestion in humans has been attributed to
autonomic activation by noncholinergic and cholinergic mecha-
nisms [39]. This is of interest with respect to the significant lower
C-peptide levels and trend for lower plasma insulin levels. C-
peptide is not cleared by the liver and other organs, and thus
reflects endogenous insulin secretion more accurately than insu-
lin [40, 41].
We analyzed baseline and postprandial bile acid concentra-
tions since bile acid homeostasis has a circadian rhythm in
both rodents and humans [39, 42, 43]. Bile acids are synthe-
sized in the liver, enter the enterohepatic cycle, and are under
control of the nuclear farnesoid X receptor [44]. Older studies
suggest that bile acid secretion may be under vagal control
[45, 46]. However, in this acute VNS setting, we could not
support this notion.
We found no effect on EE or eardrum temperature in con-
trast to previous work [21] that suggested a marginal 2.2%
increase in EE in epileptic patients stimulated every 5 min,
performing indirect calorimetry over the course of 2 h. This
discrepancy can be explained by our single bout of VNS com-
pared to more frequent stimulation in epilepsy. Of note, RA
patients received up to a maximum of 60 s stimulation eight
times a day [22]. VNS patients describe the more frequent
stimulation as mildly unpleasant, and repetitive bouts could
perhaps increase a cortisol/catecholamine response which was
not seen in our study.
This is the first study in which plasma levels of pituitary
hormones, catecholamines, metabolic activity, and postpran-
dial metabolism have been determined systemically in re-
sponse to VNS. A limitation of the study is the small num-
ber of study patients. This is still a highly novel and exper-
imental approach in RA, and only 17 RA patients have been
treated with VNS so far [22]. Since we excluded pre-existent
pituitary disease or metabolic disorders (i.e., diabetes
mellitus), six was the maximum number of eligible patients.
To strengthen the robustness of data, the results were built
on paired data for all the study patients. Another caveat is
that the included patients had already been treated
with VNS for at least 3 months; thus, effects of chronic
VNS may have obscured acute effects that would be seen
in VNS-naïve individuals. Although patients were instructed
not to employ VNS 24 h before study days, we cannot
completely exclude the possibility that this has not been
long enough. However, the strengths of our study are the
crossover design and the systematic measurements of the
Fig. 4 First-phase insulin and C-peptide secretion. AUC of 1-h
postprandial insulin (a) and C-peptide (b) concentration. Values are
mean ± SEM. †p < 0.10, *p < 0.05
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hormones and other parameters of metabolic activity on con-
secutive timepoints. Still, we would have expected an im-
mediate effect of VNS on hormone levels in light of the
infrequent dosing regimen.
VNS is a potentially promising and transformational ther-
apy for patients with inflammatory diseases as recently sug-
gested based on the first clinical trial in patients with RA
[22]. Previous animal and human studies suggest that the
vagus nerve plays a role in neuroendocrine adaptation and
therefore VNS could have affected metabolic adaptation. We
did not find any evidence for this notion if VNS is used up
to eight times a day, except perhaps for insulin secretion.
Further studies are needed to determine the effects of differ-
ent VNS durations, frequencies, and intensities. Apart from
insulin secretion, single VNS in subjects with RA that have
been treated with VNS at least 3 months has no discernible
acute effects on hormone levels or metabolism. Therefore,
this suggests VNS as a safe and effective treatment for pa-
tients suffering from rheumatoid arthritis. Furthermore, the
possible and favorable effect on insulin secretion needs to be
investigated.
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